Fluorinated fine chemicals | 제작품 - Fluoropharm Co.,Ltd

전화: +86 0571-85586753
이메일: sales@fluoropharm.com

中文版

About Us
제작품
과학 기술
Company News
문의

Fluorinated fine chemicals

LF10831 | 317-46-4 | 2-Fluoro-3-nitrobenzoic acid

EF10024 | 373-52-4 | Bromofluoromethane

TF10360 | 105184-38-1 | 3,5-Difluorophenylacetic acid

XF10063 | 1823-63-8 | 2,2,2-trifluoro-1-(4-hydroxyphenyl)ethanone

BF10004 | 66684-57-9 | 1,2,5-Trifluoro-3-nitrobenzene

BF10118 | 1017779-69-9 | 3-Fluoro-4-(trifluoromethoxy)aniline

BF12051 | 399-94-0 | 2-Bromo-1,4-difluorobenzene

KF10057 | 669-78-3 | 3,4-Difluorofuran-2,5-dione

BF12339 | 39774-02-2 | Dimethyl 2,3-difluoromaleate

BF12340 | 79322-43-3 | Dimethyl 2,3-difluorofumarate

BF12341 | 2714-32-1 | 2,3-Difluorofumaric acid

BF12342 | 685-64-3 | 2,3-Difluoromaleic acid

문의

주소

Joinhands 과학 공원 No.4028 Nanhuan (RD), 항주 (杭州), 310053 중국

전화

+86 0571-85586753

이메일

sales@fluoropharm.com

About Us

회사 소개
기업 문화
과학 기술
Company News
문의
사이트 맵

Latest News

FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis

11월 03, 2020

ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV

10월 18, 2020

European Commission Grants Marketing Authorization for Jyseleca® ▼ (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis

9월 28, 2020

Copyright © 2010-2020 Fluoropharm Co., Ltd. All rights reserved.